open access

Vol 93, No 7 (2022)
Research paper
Published online: 2021-10-06
Get Citation

Genotyping of human papillomavirus DNA in Wielkopolska region

Marcin Przybylski12, Dominik Pruski13, Sonja Millert-Kalinska14, Radoslaw Madry5, Malgorzata Lagiedo-Zelazowska6, Jan Sikora6, Andrzej Zmaczynski7, Rafal Baran7, Hanna Twardowska7, Anna Horbaczewska7, Robert Jach7
·
Pubmed: 34541643
·
Ginekol Pol 2022;93(7):546-551.
Affiliations
  1. Department of Obstetrics and Gynecology, District Public Hospital in Poznan, Poland
  2. Marcin Przybylski M.D. Gynecology Specialised Practise, Poznan, Poland
  3. Dominik Pruski M.D. Gynecology Specialised Medical Practice Poznan, Poland
  4. Poznan University of Medical Science, Poland
  5. Department of Oncology, Poznan University of Medical Sciences, Poland
  6. Department of Immunology, Chair of Patomorphology and Clinical Immunology, Poznan University of Medical Sciences, Poland
  7. Department of Gynaecological Endocrinology and Gynaecology, Jagiellonian University Medical College, Cracow, Poland

open access

Vol 93, No 7 (2022)
ORIGINAL PAPERS Gynecology
Published online: 2021-10-06

Abstract

Objectives: Human papillomavirus infection is one of the most common sexually transmitted diseases. Long-term exposure to the HPV leads to development of high-grade squamous intraepithelial lesions that can eventually transform into cervical cancer. The aim of the study was to assess the HPV genotype distribution in patients with abnormal pap smear and provide prospective study. Material and methods: We obtained material from 674 women who registered to Specialist Medical Practice in the years 2018–2020. The sample for the molecular test was collected using combi brush and forwarded to the independent, standardized laboratory. HPV detection was done using PCR followed by DNA enzyme immunoassay and reverse hybridization line probe assay for virus genotyping. Sequence analysis was performed to characterize virus genotypes in HPV — positive samples. Results: We found that 53% of patients tested positive for HPV. The percentage decreased with age. The following HPV types were the most common: HPV — 16 (24.5%), HPV — 53 (13.1%), HPV — 31 (10.3%), HPV — 51 (9.7%), HPV — 56 (9.5%). To our knowledge, this study is the largest assessment of HPV genotypes in Poland. Conclusions: Our results suggest that type-specific, high–risk HPV DNA — based screening should focus on HPV types 16, 31, 51, 56.

Abstract

Objectives: Human papillomavirus infection is one of the most common sexually transmitted diseases. Long-term exposure to the HPV leads to development of high-grade squamous intraepithelial lesions that can eventually transform into cervical cancer. The aim of the study was to assess the HPV genotype distribution in patients with abnormal pap smear and provide prospective study. Material and methods: We obtained material from 674 women who registered to Specialist Medical Practice in the years 2018–2020. The sample for the molecular test was collected using combi brush and forwarded to the independent, standardized laboratory. HPV detection was done using PCR followed by DNA enzyme immunoassay and reverse hybridization line probe assay for virus genotyping. Sequence analysis was performed to characterize virus genotypes in HPV — positive samples. Results: We found that 53% of patients tested positive for HPV. The percentage decreased with age. The following HPV types were the most common: HPV — 16 (24.5%), HPV — 53 (13.1%), HPV — 31 (10.3%), HPV — 51 (9.7%), HPV — 56 (9.5%). To our knowledge, this study is the largest assessment of HPV genotypes in Poland. Conclusions: Our results suggest that type-specific, high–risk HPV DNA — based screening should focus on HPV types 16, 31, 51, 56.

Get Citation

Keywords

HPV; HPV genotypes; HPV screening; cervical cancer

About this article
Title

Genotyping of human papillomavirus DNA in Wielkopolska region

Journal

Ginekologia Polska

Issue

Vol 93, No 7 (2022)

Article type

Research paper

Pages

546-551

Published online

2021-10-06

Page views

5071

Article views/downloads

687

DOI

10.5603/GP.a2021.0165

Pubmed

34541643

Bibliographic record

Ginekol Pol 2022;93(7):546-551.

Keywords

HPV
HPV genotypes
HPV screening
cervical cancer

Authors

Marcin Przybylski
Dominik Pruski
Sonja Millert-Kalinska
Radoslaw Madry
Malgorzata Lagiedo-Zelazowska
Jan Sikora
Andrzej Zmaczynski
Rafal Baran
Hanna Twardowska
Anna Horbaczewska
Robert Jach

References (27)
  1. Dijkstra MG, Snijders PJF, Arbyn M, et al. Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann Oncol. 2014; 25(5): 927–935.
  2. Reels J, Jones D, Chen H, et al. Interventions to improve the uptake of cervical cancer screening among lower socioeconomic groups: A systematic review. Prev Med. 2018; 111: 323–335.
  3. Stefanek A, Durka P. Women's knowledge of prevention of cervical cancer. Pol Prz Nauk Zdr. 2014; 38: 1.
  4. zur Ha. Similarities of papillomavirus infections with tumor promoters. Princess Takamatsu Symp. 1983; 14: 147–52.
  5. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009; 384(2): 260–265.
  6. Wilkinson DE, Baylis SA, Padley D, et al. Collaborative Study Group. Establishment of the 1st World Health Organization international standards for human papillomavirus type 16 DNA and type 18 DNA. Int J Cancer. 2010; 126(12): 2969–2983.
  7. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007; 121(3): 621–632.
  8. Marth C, Landoni F, Mahner S, et al. ESMO Guidelines Committee. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4): iv72–iv83.
  9. Fontham E, Wolf A, Church T, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians. 2020; 70(5): 321–346.
  10. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012; 100: 1–441.
  11. International Agency for Research on Cancer (IARC). The Grants Register 2018. IARC Monogr Eval Carcinog Risks Hum. 2018: 412–413.
  12. Smolarz B, Samulak D, Szyłło K, et al. Cobas 4800 HPV detection in cervical samples of Polish women. Contemp Oncol (Pozn). 2019; 23(2): 92–95.
  13. Bedziński M, Józefiak A, Szczepańska M, et al. [The correlation of a positive DNA HPV HR test and genotyping human papilloma viruses with the presence of CIN, in women with cytologic evidence of ASC-US and LSIL]. Ginekol Pol. 2008; 79(7): 490–493.
  14. Kedzia W, Pruski D, Józefiak A, et al. [Genotyping of oncogenic human papilloma viruses in women with HG SIL diagnosis]. Ginekol Pol. 2010; 81(10): 740–744.
  15. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer. 2009; 4: 8.
  16. Tsuda H, Hashiguchi Y, Nishimura S, et al. Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. Gynecol Oncol. 2003; 91(3): 476–485.
  17. Stoler MH, Castle PE, Solomon D, et al. American Society for Colposcopy and Cervical Pathology. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007; 127(3): 335–337.
  18. Giorgi-Rossi P, Carozzi F. New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of hu- man papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomized con- trolled trial. Lancet Oncol. 2010; 11: 249–257.
  19. Raab SS. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. Yearbook of Pathology and Laboratory Medicine. 2013; 2013: 273–275.
  20. Stoler MH, Wright TC, Sharma A, et al. ATHENA (Addressing THE Need for Advanced HPV Diagnostics) Study Group. The interplay of age stratification and HPV testing on the predictive value of ASC-US cytology. Results from the ATHENA HPV study. Am J Clin Pathol. 2012; 137(2): 295–303.
  21. Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003; 89(1): 101–105.
  22. de Sanjose S, Quint WGv, Alemany L, et al. Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11): 1048–1056.
  23. Cuzick J, Ho L, Terry G, et al. Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions. J Clin Virol. 2014; 60(1): 44–49.
  24. Franceschi S, Clifford GM. Re: A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005; 97(12): 938–939.
  25. Nakamura Y, Matsumoto K, Satoh T, et al. HPV genotyping for triage of women with abnormal cervical cancer screening results: a multicenter prospective study. Int J Clin Oncol. 2015; 20(5): 974–981.
  26. Xi LFu, Schiffman M, Koutsky LA, et al. Lineages of oncogenic human papillomavirus types other than type 16 and 18 and risk for cervical intraepithelial neoplasia. J Natl Cancer Inst. 2014; 106(10).
  27. Xu L, Benoy I, Cuschieri K, et al. Accuracy of genotyping for HPV16 and 18 to triage women with low-grade squamous intraepithelial lesions: a pooled analysis of VALGENT studies. Expert Rev Mol Diagn. 2019; 19(6): 543–551.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl